Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.

Archives of disease in childhood - 1 Mar 2006

Massie J, Curnow L, Tzanakos N, Francis I, Robertson C F

Abstract excerpt

AIMS: To investigate the immunoreactive trypsinogen (IRT) values above the usual 99th centile laboratory cut-off and determine the value of offering further testing to those infants with a markedly elevated IRT but no cystic fibrosis transmembrane regulator (CFTR) gene mutation identified by the screening programme. METHODS: All babies born in Victoria, Australia, between 1991 and 2003, were screened by IRT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Cystic Fibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to False Positive Reactions

Share to Homozygote

Share to Neonatal Screening

Share to Reference Values

Share to Trypsinogen

Source

Open in PubMed Open full text

Identifiers

PMID: 16243854
DOI: 10.1136/adc.2005.081349
PMCID: PMC2065933

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Markedly elevated neonatal immunoreactive trypsinogen levels in the absence of cystic fibrosis gene mutations is not an indication for further testing.PMID 16243854Read ↗

Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.Semantic proximity Read ↗

Cystic fibrosis newborn screening in a high prevalence population - Ten years' experience in Ireland.Semantic proximity Read ↗

Cystic fibrosis identified by neonatal screening: incidence, genotype, and early natural history.Semantic proximity Read ↗

National Newborn Screening for cystic fibrosis in the Republic of Ireland: genetic data from the first 6.5 years.Semantic proximity Read ↗

Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations.Semantic proximity Read ↗

Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.Semantic proximity Read ↗

Utility of a very high IRT/No mutation referral category in cystic fibrosis newborn screening.Semantic proximity Read ↗

Neonatal screening for cystic fibrosis: result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses.Semantic proximity Read ↗

Blood immunoreactive trypsinogen concentrations are genetically determined in healthy and cystic fibrosis newborns.Semantic proximity Read ↗

Thirty-years of screening for cystic fibrosis in East Anglia.Semantic proximity Read ↗

Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.Semantic proximity Read ↗

Cystic fibrosis newborn screening: outcome of infants with normal sweat tests.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.